Assessment of Tear Concentrations on Therapeutic Drug Monitoring. III. Determination of Theophylline in Tears by Gas Chromatography/Mass Spectrometry with Electron Ionization Mode

Drug Metabolism and Pharmacokinetics

Volumn 18, Issue 2, 2003, Pages 139-145

  Nakajima, Masaharu ^a   Yamato, Susumu ^a   Shimada, Kenji ^a   Sato, Shinji ^a   Kitagawa, Shuji ^a   Honda, Akira ^b   Miyamoto, Jiro ^b   Hirano, Harunobu ^c   Suzuki, Mitsuyuki ^c   Miyazaki, Hiroshi ^a  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b Miyamoto Hospital   (Japan)

^c Saiseikai Niigata Daini Hospital   (Japan)

Author keywords

GC EI MS; pentafluorobenzoyl derivative; plasma; quantitation; tears; theophylline

Indexed keywords

EID: 85011761686     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.18.139     Document Type: Article

References (17)

1. Stirt, J. A. and Sullivan, S. F.: Aminophylline. Anesth. Analg., 60: 587-602 (1981).
2. Koup, J. R., Schentag, J. J., Vance, J. W., Kuritzky, P. M., Pyszczynski, D. R. and Jusko, W. J.: System for clinical pharmacokinetic monitoring of theophylline therapy. Am. J. Hosp. Pharm., 33: 949-956 (1976).
3. Ramzan, I. M. and Levy, G.: Kinetics of drug action in disease states. XVI. Pharmacodynamics of theophylline-induced seizures in rats. J. Pharmacol. Exp. Ther., 236: 708-713 (1986).
4. Mally, J., Keszei, C. and Cserep, G.: Theophylline concentrations in serum, saliva, and cerebrospinal fluid in patients with essential tremor. Ther. Drug. Monit., 14: 135-137 (1992).
5. Nishijo, J. and Morita, N.: Binding parameters of theophylline and aminophylline to bovine serum albumin. Chem. Pharm. Bull., 33: 2522-2524 (1985).
6. Trnavska, Z.: Theophylline protein binding. Arzneimittelforschung. 40: 166-169 (1990).
7. Shaw, L. M., Fields, L. and Mayock, R.: Factors influencing theophylline serum protein binding. Clin. Pharmacol. Ther., 32: 490-496 (1982).
8. Lesko, L. J., Tabor, K. J. and Johnson, B. F.: Theophylline serum protein binding in obstructive airways disease. Clin. Pharmacol. Ther., 29: 776-781 (1981).
9. Zarowitz, B., Shiom, J., Eichenhorn, M. S. and Popovich, J. Jr.: Alterations in theophylline protein binding in acutely ill patients with COPD. Chest., 87: 766-769 (1985).
10. Leopold, D., Webb, D., Buss, D. C., Fifield, R. A., Smith, A. P. and Routledge, P. A.: The ex vivo plasma protein binding of theophylline in renal disease. Br. J. Clin. Pharmacol., 19: 823-825 (1985).
11. Stoehr, G. P., Venkataramanan, R. and Dauber, J. H.: Comparison of methods for determining unbound theophylline concentrations. Ther. Drug Monit., 8: 42-46 (1986).
12. Nakajima, M., Yamato, S., Shimada, K., Sato, S., Kitagawa, S., Honda, A., Miyamoto, J., Shoda, J. and Miyazaki, H.: Assessment of drug concentrations in tears in therapeutic drug monitoring: I. Determination of valproic acid in tears by gas chromatography/mass spectrometry with EC/NCI mode. Ther. Drug. Monit., 22: 716-722 (2000).
13. Sato, S., Kitagawa, S., Nakajima, M., Shimada, K., Honda, A. and Miyazaki, H.: Assessment of tear concentrations on therapeutic drug monitoring. II. Pharmacokinetic analysis of valproic acid in guinea pig serum, cerebrospinal fluid and tears. Pharm. Res., 18: 500-509 (2001).
14. Blanchard, J. and Harvey, S.: Comparison of ultrafiltration devices for assessing theophylline protein binding. Ther. Drug. Monit., 12: 398-403 (1990).
15. Schwertner, H. A., Ludden, T. M. and Wallace, J. E.: Determination of theophylline in plasma by electron capture gas chromatography. Anal. Chem., 48: 1875-1878 (1976).
16. Shargel, L., Yu, A. eds. Applied biopharmaceutics and pharmacokinetics, 4th ed. Norwalk, CT: Appleton and Lange, 1999: 99-128.
17. Simons, K. J., Simons, F. E. R., Briggs, C. J. and Lo, L.: Theophylline protein binding in humans. J. Pharm. Sci., 68: 252-253 (1979).